When should I prescribe Nplate® for my patients with adult chronic immune thrombocytopenia (ITP)?
Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.1
Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than chronic ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.1Review the Nplate® pivotal trials data
How is Nplate® administered or dosed?
Nplate® is administered once weekly by subcutaneous injection. The initial dose for Nplate® is 1 mcg/kg based on the patient's actual body weight at initiation.1 Please refer to the full Prescribing Information for complete dosing and administration information including reconstitution, dose adjustments, and monitoring requirements. 1Full Prescribing Information
How quickly does Nplate® work, and when may a platelet response become apparent?
Individual responses on Nplate® will vary from patient to patient.
In the two parallel, double-blind, phase 3 trials, patients with ITP who had completed at least one prior treatment and had a platelet count of ≤ 30 x 109/L prior to study entry were randomized (2:1) to 24 weeks of Nplate® (1 mcg/kg subcutaneous) or placebo., 1,7
Dose adjustments were based on platelet counts. Patients could have doses of concurrent ITP medications adjusted only during the first 12 weeks., 1,7
- A durable platelet response was the achievement of a weekly platelet count ≥ 50 x 109/L for any 6 of the last 8 weeks of the 24-week treatment period in the absence of rescue medication at any time. , 1,7
- A transient platelet response was the achievement of weekly platelet counts ≥ 50 x 109/L for any 4 weeks during the treatment period without a durable platelet response. , 1,7
- An overall platelet response was the achievement of either a durable or a transient platelet response. Platelet responses were excluded for 8 weeks after receiving rescue medications. , 1,7
Weeks 0-3 platelet counts across two 6-month pivotal trials
50% of patients achieved median platelet counts of ≥ 50 x 109/L within 2-3 weeks. 7
Durable platelet response
61% of non-splenectomized patients achieved a durable platelet response during the last 8 weeks of the study. , 1,7
What if a patient misses a dose of Nplate®? What should patients do if they’re traveling and cannot visit their physician for their weekly dose of Nplate®?
If a patient misses their scheduled dose of Nplate®, they should call their healthcare provider to arrange for their next dose as soon as possible.
If a patient plans to travel, the patient or their healthcare provider can call Nplate® Navigator in advance at 1-855-7Nplate (1-855-767-5283). An Nplate® Navigator patient support specialist will access a list of board-certified physicians who may be able to give the patient their Nplate® injection at their destination.
Please note that Amgen does not endorse or recommend any healthcare provider. In consultation with their healthcare provider, the patient should make his or her own decision regarding their treatment options.Learn more about Nplate® Navigator
Who should I contact if I have a question about Nplate® or would like to report an adverse event?
If you have a clinical question about Nplate® or would like to report an adverse event related to Nplate®, please contact Amgen Medical Information. Amgen healthcare professionals can be accessed 24/7.Click here to connect